# Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

> **NCT02829814** · PHASE3 · TERMINATED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 51 (actual)

## Conditions studied

- Fibromyalgia
- Myofascial Pain Syndromes
- Muscular Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Rheumatic Diseases
- Musculoskeletal Diseases

## Interventions

- **DRUG:** TNX-102 SL Tablet, 2.8 mg
- **DRUG:** Placebo SL Tablet

## Key facts

- **NCT ID:** NCT02829814
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-22
- **Primary completion:** 2016-09-13
- **Final completion:** 2016-09-13
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** For business reason unrelated to safety or tolerability,Tonix discontinued this study.
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02829814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02829814, "Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02829814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*